Ballentine Partners’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $227K | Buy |
+8,226
| New | +$227K | ﹤0.01% | 824 |
|
|
2024
Q3 | – | Sell |
-4,564
| Closed | -$542K | – | 869 |
|
|
2024
Q2 | $542K | Sell |
4,564
-183
| -4% | -$21.7K | 0.01% | 391 |
|
|
2024
Q1 | $506K | Buy |
4,747
+2,641
| +125% | +$281K | 0.01% | 386 |
|
|
2023
Q4 | $209K | Sell |
2,106
-876
| -29% | -$87.1K | ﹤0.01% | 606 |
|
|
2023
Q3 | $308K | Buy |
2,982
+868
| +41% | +$89.7K | 0.01% | 439 |
|
|
2023
Q2 | $257K | Sell |
2,114
-646
| -23% | -$78.5K | 0.01% | 477 |
|
|
2023
Q1 | $424K | Sell |
2,760
-166
| -6% | -$25.5K | 0.01% | 329 |
|
|
2022
Q4 | $526K | Buy |
2,926
+414
| +16% | +$74.4K | 0.02% | 271 |
|
|
2022
Q3 | $297K | Buy |
2,512
+594
| +31% | +$70.2K | 0.01% | 342 |
|
|
2022
Q2 | $273K | Buy |
1,918
+100
| +6% | +$14.2K | 0.01% | 343 |
|
|
2022
Q1 | $314K | Buy |
1,818
+24
| +1% | +$4.15K | 0.01% | 344 |
|
|
2021
Q4 | $455K | Sell |
1,794
-1
| -0.1% | -$254 | 0.01% | 291 |
|
|
2021
Q3 | $691K | Buy |
1,795
+186
| +12% | +$71.6K | 0.02% | 196 |
|
|
2021
Q2 | $378K | Sell |
1,609
-34
| -2% | -$7.99K | 0.01% | 281 |
|
|
2021
Q1 | $215K | Buy |
+1,643
| New | +$215K | 0.01% | 367 |
|